Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANAB 
AnaptysBio Inc (ANAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ANAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $45.5
1 Year Target Price $45.5
| 7 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.31% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 542.68M USD | Price to earnings Ratio - | 1Y Target Price 45.5 |
Price to earnings Ratio - | 1Y Target Price 45.5 | ||
Volume (30-day avg) 12 | Beta -0.18 | 52 Weeks Range 12.21 - 39.50 | Updated Date 09/17/2025 |
52 Weeks Range 12.21 - 39.50 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -107.66% | Operating Margin (TTM) -117.55% |
Management Effectiveness
Return on Assets (TTM) -14.12% | Return on Equity (TTM) -343.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 292062141 | Price to Sales(TTM) 4.41 |
Enterprise Value 292062141 | Price to Sales(TTM) 4.41 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA -1.3 | Shares Outstanding 27973000 | Shares Floating 15983186 |
Shares Outstanding 27973000 | Shares Floating 15983186 | ||
Percent Insiders 5.82 | Percent Institutions 124.31 |
Upturn AI SWOT
AnaptysBio Inc
Company Overview
History and Background
AnaptysBio, Inc. is a biotechnology company founded in 2005. It focuses on developing antibody therapeutics, particularly for inflammatory diseases. They initially focused on antibody discovery technologies and have transitioned to clinical development of their own pipeline.
Core Business Areas
- Antibody Discovery: AnaptysBio's initial core was their proprietary antibody discovery platform, SHM-XEL, which uses somatic hypermutation (SHM) to create antibodies with optimized properties.
- Therapeutic Development: Focuses on developing antibody therapeutics targeting inflammatory diseases. This includes programs in dermatology and other areas where inflammation plays a key role.
Leadership and Structure
AnaptysBio has a management team led by a CEO and CFO, overseeing various departments like Research, Clinical Development, and Business Development. The board of directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Imsidolimab (anti-IL-36R antibody): AnaptysBiou2019s primary focus is Imsidolimab, an anti-IL-36R antibody in clinical development for generalized pustular psoriasis (GPP), palmo-plantar pustulosis (PPP), and acne. Precise market share data is not publicly available for these specific indications. Competitors include companies developing other IL-36 inhibitors and treatments for these dermatological conditions (e.g., Boehringer Ingelheim with spesolimab).
- Rosnilimab (anti-PD-1 antibody): Rosnilimab (formerly JTX-4014), an anti-PD-1 agonist antibody, was in development for cancer treatment. AnaptysBio licensed it to Bristol Myers Squibb (BMY). Revenue is tied to milestones and royalties from BMY, market share is not directly applicable as AnaptysBio is not actively marketing it. Competitors are other PD-1 agonists and cancer therapies being developed by various companies (e.g., BMS, Merck).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. The market for inflammatory disease treatments is large and growing, driven by aging populations and increased disease prevalence.
Positioning
AnaptysBio positions itself as a developer of novel antibody therapeutics for inflammatory diseases. Their competitive advantage lies in their SHM-XEL antibody discovery platform and their focus on specific inflammatory pathways like IL-36R.
Total Addressable Market (TAM)
The total addressable market for inflammatory disease treatments is estimated to be in the tens of billions of dollars. AnaptysBio is positioned to capture a portion of this market with its lead product candidate, Imsidolimab, targeting specific indications like GPP and PPP.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform (SHM-XEL)
- Focus on specific inflammatory pathways
- Potential first-in-class therapeutics like Imsidolimab
- Partnership with Bristol Myers Squibb
Weaknesses
- Limited number of pipeline products
- Reliance on clinical trial success
- High cash burn rate
- Competition from established pharmaceutical companies
Opportunities
- Expansion of Imsidolimab into other indications
- Out-licensing or partnering of other pipeline assets
- Potential for breakthrough therapy designation
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- LLY
- ABBV
- NVS
Competitive Landscape
AnaptysBio faces significant competition from large pharmaceutical companies with greater resources. Their advantage lies in their focused approach and potentially first-in-class therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the progression of pipeline assets and partnerships.
Future Projections: Future growth is dependent on the success of Imsidolimab in clinical trials and regulatory approval. Analyst estimates would need to be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing Imsidolimab through clinical trials, exploring new indications for Imsidolimab, and seeking partnerships.
Summary
AnaptysBio is a clinical-stage biotechnology company primarily focused on Imsidolimab. Success hinges on Imsidolimab's clinical trials. The company has partnerships, providing revenue and validation, but faces risks inherent in drug development. Their proprietary technology gives them an edge, however, competitors in the space are significantly larger. Securing funding and positive data will be critical to its success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AnaptysBio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2017-01-26 | President, CEO & Director Mr. Daniel R. Faga | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://www.anaptysbio.com |
Full time employees 136 | Website https://www.anaptysbio.com | ||
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.